Scilex Holding Company

NASDAQ:SCLX

Drug Manufacturers - General

Healthcare
$6.34 -2.38%

-$0.17 today

Market cap
$53.83M
Beta
1.71
P/E (TTM)
-0.1
EPS (TTM)
-$60.90
52W Low $2.62High $21.34

Volume 0.00M

Average 0.13M

SCLX Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Scilex Holding CompanyNASDAQ: SCLX

Gross Margin · Q1 FY2026 · quarter ended Mar 2026

Gross margin narrows to 48.4%

Gross margin was 48.4% in Q1 FY2026, down 24.0 pp from a year earlier. On a trailing-twelve-month basis it was 55.0%, down 17.0 pp year over year. Over 3 fiscal years it narrowed by 21.9 pp.

Context

  • Gross margin widened in 1 of the last 3 fiscal years.
  • FY2025 was the lowest level in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
48.4%+36.0 pp QoQ
Last fiscal yearDec 2025
49.7%-20.8 pp YoY
LTMMar 2026
55.0%-17.0 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-24.0 pp——
1 year-20.8 pp——
3 years-21.9 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
49.7%
Year-over-year change
-20.8pp

Gross Margin vs competitors

How SCLX compares with its peers on the latest reported figures

  • SCLX's LTM Mar 2026 gross margin of 55.0% is the 3rd highest of the 8 companies compared; the peer median is 49.6%.
  • Its year-over-year change of -17.0 pp is the 6th highest of 7, against a peer median of +12.6 pp.
  • Over three fiscal years its change of -21.9 pp compares with a peer median of +4.6 pp.
SCLX Competitors Peer median
Gross Margin for SCLX and competitors
Company Period LTM level YoY 3-year change
INOInovio Pharmaceuticals, Inc.FY2025100.0% +0.0 pp+0.0 pp
CTORCitius Oncology, Inc.LTM Mar 202680.1% ——
SCLXScilex Holding CompanyLTM Mar 202655.0% -17.0 pp-21.9 pp
AGENAgenus Inc.LTM Mar 202652.1% +86.4 pp+130.9 pp
IRDOpus Genetics, Inc.LTM Mar 202649.6% +6.6 pp+0.0 pp
SEERSeer, Inc.LTM Mar 202648.3% +18.6 pp+9.2 pp
LUCDLucid Diagnostics Inc.LTM Mar 2026-40.0% +27.6 pp+798.4 pp
ALECAlector, Inc.LTM Mar 2026-61.2% -68.0 pp-45.9 pp
ABOSAcumen Pharmaceuticals, Inc.FY2025— ——
Peer median (excluding SCLX) 49.6%+12.6 pp+4.6 pp

Competitors are the stored peer set for SCLX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue31.32M38.03M46.74M56.59M30.25M
Cost of Revenue3.63M10.8M15.68M16.69M15.22M
Gross Profit27.68M27.24M31.06M39.9M15.03M
Gross Margin88.4%71.6%66.5%70.5%49.7%
Research & Development9.2M9.05M12.75M9.64M20.71M
Selling, General & Admin50.58M64.9M119.64M119.02M266.63M
Operating Expenses63.52M77.87M136.49M123.3M287.34M
Depreciation & Amortization3.78M4.45M4.15M4.05M4.62M
EBITDA(72.88M)(9.3M)(109.1M)(66.8M)(357.95M)
EBITDA Margin-232.7%-24.5%-233.4%-118.0%-1183.2%
Operating Income(35.84M)(50.63M)(105.43M)(83.4M)(272.3M)
Operating Margin-114.4%-133.1%-225.6%-147.4%-900.1%
Interest Income00000
Interest Expense11.76M9.6M1.07M1.96M11.46M
Other Income / Expenses(52.58M)27.27M(8.89M)10.59M(101.72M)
Income Before Tax(88.42M)(23.36M)(114.32M)(72.81M)(374.03M)
Pre-Tax Margin-282.3%-61.4%-244.6%-128.7%-1236.3%
Income Tax Expense5K4K13K(1K)26K
Net Income(88.42M)(23.36M)(114.33M)(72.81M)(358.73M)
Net Margin-282.4%-61.4%-244.6%-128.7%-1185.8%
EPS (Basic)(23.29)(6.09)(44.85)(19.43)(36.48)
EPS (Diluted)(23.29)(6.09)(44.85)(19.43)(36.48)
Weighted Avg Shares3.8M3.83M3.72M6.95M11.03M
Weighted Avg Shares (Diluted)3.8M3.83M3.72M6.95M11.03M

Scilex Holding Company

NASDAQ:SCLX

Intrinsic Alpha fair value

Locked

Current Price

$6.34

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.